Why Summit Therapeutics Inc.’s (SMMT) Stock Is Down 5.68%
As of Tuesday, July 28, Summit Therapeutics Inc.’s SMMT share price has dipped by 5.68%, which has investors questioning if this is right time to buy.Rosalio Madrigal
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis for the treatment of non-small lung cancer (NSCLC) and colorectal cancer (CRC). The company has also combined ivonescimab with chemotherapy, which is in phase III clinical trial for the patients with epidermal growth factor receptor, mutated, and locally advanced or metastatic non-squamous NSCLC; first-line metastatic NSCLC; and first-line unresectable metastatic CRC. It markets its products in the United states, Canada, Europe, Japan, Latin America, Middle East, and Africa. The company was founded in 2003 and is headquartered in Miami, Florida.
Commentary & Analysis
Why Summit Therapeutics Inc.’s (SMMT) Stock Is Down 6.88%
As of Friday, July 24, Summit Therapeutics Inc.’s SMMT share price has dipped by 6.88%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Why Summit Therapeutics Inc.’s (SMMT) Stock Is Up 5.19%
As of Tuesday, July 21, Summit Therapeutics Inc.’s SMMT share price has surged by 5.19%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Why Summit Therapeutics Inc.’s (SMMT) Stock Is Down 5.51%
As of Thursday, July 16, Summit Therapeutics Inc.’s SMMT share price has dipped by 5.51%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Summit Therapeutics Inc.’s (SMMT) Stock Is Up 6.47%
As of Thursday, July 02, Summit Therapeutics Inc.’s SMMT share price has surged by 6.47%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Financial Summary
| Share Statistics | SMMT | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $10,386.7 | $252.6 | 78% |
|
| Shares Out (Mil) | 778.2 | 52.3 | 92% |
|
| Institutional Ownership | 16.5% | 92.1% | 9% |
|
| Float (Mil) | 152.3 | 40.2 | 69% |
|
| Beta | -1.26 | 0.95 | 1% |
|
| Avg Daily Volume (000s) | 4,316 | 455 | 91% |
|
| Price Change (52-week) |
(51.2%) | 52.9% | 15% |
|
| Growth | SMMT | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.6% | na |
|
| Net Income (5yr) | (82.9%) | (9.9%) | 3% |
|
| EPS (5yr) | (13.7%) | 16.0% | 19 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | 32.0% | (15.6%) | 87% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 12 | 12 | na | |
| Current EPS | ($0.291) | ($1.157) | na | |
| Month Ago EPS | ($0.295) | ($1.110) | na | |
| # Rev Up | 0 | 0 | na | |
| # Rev Down | 1 | 1 | na | |
| Three Months Ago EPS | ($0.319) | ($1.060) | na | |
| Year/Year Chg | 3.9% | (19.9%) | (17.1%) | |
| Financials | SMMT | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $38 | na |
|
| Net Income (TTM) (Mil) | ($856) | ($43) | 2% |
|
| EPS (TTM) | ($1.118) | ($1.600) | 20% |
|
| Operating Cash Flow (TTM) (Mil) | ($458) | ($31) | 2% |
|
| Net Cash Flow (TTM) (Mil) | $122 | $5 | 80% |
|
| Long-Term Debt (Q1) (Mil) | $17 | $5 | 32% |
|
| Enterprise Value (Q1) (Mil) | $10,227 | $180 | 74% |
|
| Valuation | SMMT | Industry Median |
Percentile (All Stocks) |
|
| P/B | 16.48 | 2.56 | 94% |
|
| P/E | na | 19.0 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 0.9 | na |
|
| Ratios | SMMT | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 63.8% | na |
|
| Net Margin | na | (67.3%) | na |
|
| ROA | (159.1%) | (49.8%) | 3% |
|
| ROE | (192.5%) | (55.5%) | 5% |
|
| Liabilities to Assets | 16.2% | 30.3% | 10% |
|
| F-Score | 3 | 3 | 19% |
|
Summit Therapeutics Inc. did not pass any screens on 7/31/2026.
